Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH

Background Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by hepatic steatosis, lobular inflammation and fibrosis. Acetyl-CoA carboxylase (ACC) isoform 1 and 2 involved in de novo lipogenesis (DNL) and fatty acid oxidation have been identified as a therapeutic targ...

Full description

Bibliographic Details
Main Authors: Ying Lu, Xiaolan Su, Manyu Zhao, Qianru Zhang, Chuang Liu, Qinhuai Lai, Sijia Wu, Aiping Fang, Jinliang Yang, Xiaoxin Chen, Yuqin Yao
Format: Article
Language:English
Published: PeerJ Inc. 2019-12-01
Series:PeerJ
Subjects:
Online Access:https://peerj.com/articles/8115.pdf
id doaj-d85f191eb5f440d5a5ebd2c53db8a694
record_format Article
spelling doaj-d85f191eb5f440d5a5ebd2c53db8a6942020-11-25T02:17:43ZengPeerJ Inc.PeerJ2167-83592019-12-017e811510.7717/peerj.8115Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASHYing Lu0Xiaolan Su1Manyu Zhao2Qianru Zhang3Chuang Liu4Qinhuai Lai5Sijia Wu6Aiping Fang7Jinliang Yang8Xiaoxin Chen9Yuqin Yao10State Key Laboratory of Biotherapy and Cancer Center, West China Hospital and Healthy Food Evaluation Research Center, Sichuan University, Chengdu, ChinaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital and Healthy Food Evaluation Research Center, Sichuan University, Chengdu, ChinaWest China School of Public Health and West China Fourth Hospital, Healthy Food Evaluation Research Center, Sichuan University, Chengdu, ChinaWest China School of Public Health and West China Fourth Hospital, Healthy Food Evaluation Research Center, Sichuan University, Chengdu, ChinaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital and Healthy Food Evaluation Research Center, Sichuan University, Chengdu, ChinaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital and Healthy Food Evaluation Research Center, Sichuan University, Chengdu, ChinaWest China School of Public Health and West China Fourth Hospital, Healthy Food Evaluation Research Center, Sichuan University, Chengdu, ChinaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital and Healthy Food Evaluation Research Center, Sichuan University, Chengdu, ChinaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital and Healthy Food Evaluation Research Center, Sichuan University, Chengdu, ChinaGuangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan, ChinaWest China School of Public Health and West China Fourth Hospital, Healthy Food Evaluation Research Center, Sichuan University, Chengdu, ChinaBackground Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by hepatic steatosis, lobular inflammation and fibrosis. Acetyl-CoA carboxylase (ACC) isoform 1 and 2 involved in de novo lipogenesis (DNL) and fatty acid oxidation have been identified as a therapeutic target in NASH. GS-0976, the inhibitor of ACC1 and ACC2, has achieved favorable therapeutic effects in clinical trials with NASH. The purpose of this study was to explore the transcriptional alterations regulated by GS-0976 in NASH. Methods C57BL/6 mice were fed on a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) or normal diet for 12 weeks. Mice were treated with or without GS-0976 (3 mg/kg per day) in the last 8 weeks. Oil Red O, Haematoxylin-eosin (H & E), and Sirius Red were used to evaluate hepatic steatosis, inflammation and fibrosis. The comparative RNA-sequencing was conducted to analyse the hepatic gene expression profiles in mice. Reverse transcription–polymerase chain reaction analysis was performed to validate the differential expression of representative genes. Results GS-0976 attenuated the steatosis, inflammation, and fibrosis of NASH in CDAHFD mouse model. High-throughput sequencing and differential gene expression analysis showed that there were 516 up-regulated genes and 525 down-regulated genes after GS-0976 treatment. Genes involved in the metabolic process, extracellular matrix formation, immune response, and angiogenesis were significantly enriched. The “Metabolic pathways” and “ECM-receptor interaction” pathways were the most significantly enriched KEGG pathways in the up-regulated and down-regulated differentially expressed genes (DEGs), respectively. Conclusions Transcriptome analysis showed that GS-0976 could regulate the expression of genes related to metabolism, inflammation and fibrosis in NASH. The global transcriptomic changes in gene expression promote the further understanding for the inhibition mechanisms of GS-0976 in NASH.https://peerj.com/articles/8115.pdfTranscriptomeRNA-SeqNon-alcoholic steatohepatitisAcetyl-CoA carboxylase inhibitor
collection DOAJ
language English
format Article
sources DOAJ
author Ying Lu
Xiaolan Su
Manyu Zhao
Qianru Zhang
Chuang Liu
Qinhuai Lai
Sijia Wu
Aiping Fang
Jinliang Yang
Xiaoxin Chen
Yuqin Yao
spellingShingle Ying Lu
Xiaolan Su
Manyu Zhao
Qianru Zhang
Chuang Liu
Qinhuai Lai
Sijia Wu
Aiping Fang
Jinliang Yang
Xiaoxin Chen
Yuqin Yao
Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
PeerJ
Transcriptome
RNA-Seq
Non-alcoholic steatohepatitis
Acetyl-CoA carboxylase inhibitor
author_facet Ying Lu
Xiaolan Su
Manyu Zhao
Qianru Zhang
Chuang Liu
Qinhuai Lai
Sijia Wu
Aiping Fang
Jinliang Yang
Xiaoxin Chen
Yuqin Yao
author_sort Ying Lu
title Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
title_short Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
title_full Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
title_fullStr Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
title_full_unstemmed Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
title_sort comparative rna-sequencing profiled the differential gene expression of liver in response to acetyl-coa carboxylase inhibitor gs-0976 in a mouse model of nash
publisher PeerJ Inc.
series PeerJ
issn 2167-8359
publishDate 2019-12-01
description Background Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by hepatic steatosis, lobular inflammation and fibrosis. Acetyl-CoA carboxylase (ACC) isoform 1 and 2 involved in de novo lipogenesis (DNL) and fatty acid oxidation have been identified as a therapeutic target in NASH. GS-0976, the inhibitor of ACC1 and ACC2, has achieved favorable therapeutic effects in clinical trials with NASH. The purpose of this study was to explore the transcriptional alterations regulated by GS-0976 in NASH. Methods C57BL/6 mice were fed on a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) or normal diet for 12 weeks. Mice were treated with or without GS-0976 (3 mg/kg per day) in the last 8 weeks. Oil Red O, Haematoxylin-eosin (H & E), and Sirius Red were used to evaluate hepatic steatosis, inflammation and fibrosis. The comparative RNA-sequencing was conducted to analyse the hepatic gene expression profiles in mice. Reverse transcription–polymerase chain reaction analysis was performed to validate the differential expression of representative genes. Results GS-0976 attenuated the steatosis, inflammation, and fibrosis of NASH in CDAHFD mouse model. High-throughput sequencing and differential gene expression analysis showed that there were 516 up-regulated genes and 525 down-regulated genes after GS-0976 treatment. Genes involved in the metabolic process, extracellular matrix formation, immune response, and angiogenesis were significantly enriched. The “Metabolic pathways” and “ECM-receptor interaction” pathways were the most significantly enriched KEGG pathways in the up-regulated and down-regulated differentially expressed genes (DEGs), respectively. Conclusions Transcriptome analysis showed that GS-0976 could regulate the expression of genes related to metabolism, inflammation and fibrosis in NASH. The global transcriptomic changes in gene expression promote the further understanding for the inhibition mechanisms of GS-0976 in NASH.
topic Transcriptome
RNA-Seq
Non-alcoholic steatohepatitis
Acetyl-CoA carboxylase inhibitor
url https://peerj.com/articles/8115.pdf
work_keys_str_mv AT yinglu comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
AT xiaolansu comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
AT manyuzhao comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
AT qianruzhang comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
AT chuangliu comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
AT qinhuailai comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
AT sijiawu comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
AT aipingfang comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
AT jinliangyang comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
AT xiaoxinchen comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
AT yuqinyao comparativernasequencingprofiledthedifferentialgeneexpressionofliverinresponsetoacetylcoacarboxylaseinhibitorgs0976inamousemodelofnash
_version_ 1724885677618757632